The primary objective of this first human clinical study on ImVisioN’s lead product IVN201 for the treatment of cat dander allergies will be product safety, but the study will also assess several efficacy parameters. The first patient has been enrolled for this placebo controlled, double blind trial, conducted at the University Hospital in Zurich, Switzerland. The study will include a total of 20 patients allergic to cat dander and is expected to complete in the second quarter of 2009.
“Aravis Venture is delighted to be leading this investment in ImVisioN,” said Simon Nebel, Managing Partner at Aravis Venture Associates. “Current treatments for severe allergies are largely ineffective or so unpleasant that they have very poor compliance. ImVisioN’s approach has the potential to offer effective and fast treatment solutions with higher patient compliance.”
Martin Steiner, ImVisioN’s Chief Executive Officer and Co-Founder, added: “This financing allows ImVisioN to conduct the first human studies on IVN201 for the treatment of cat dander allergy. This intralymphatic immunotherapeutic allows for the treatment of this common allergy with a minimum of injections leading to faster and more effective desensitization. This is the first product in our pipeline, which also includes treatments for other frequent allergies such as those caused by birch pollen or house dust mites.”
ImVisioN Therapeutics AG is a Swiss company that has been founded by ImVisioN Therapeutics Inc. (US) and now owns 100% of ImVisioN GmbH in Germany, Hannover.
